Psychedelics and neurostimulation for treatment resistant psychiatric disorders.
Filip Blazek, Klara Latalova, David Krahulik, Lumir Hrabalek
Discover mental health May 25, 2026 DOI: 10.1007/s44192-026-00486-5 via PubMed
Summary
AI-generated from the abstractPsychedelic-assisted therapy and neurostimulation both aim to alter malfunctioning brain circuits in treatment-resistant psychiatric conditions. This Perspective identifies overlapping mechanisms—neuroplasticity and network reconfiguration—that underlie both approaches. It also considers ethical, regulatory, and practical obstacles to bringing these treatments into clinical use. By connecting neuroscience, psychiatry, and policy, the authors suggest ways to incorporate these novel interventions into evidence-based, circuit-oriented mental health care.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Key finding | Psychedelic-assisted therapy and neurostimulation share mechanisms of neuroplasticity and network reconfiguration, and integrating them into circuit-focused mental health care requires addressing ethical, regulatory, and infrastructural barriers. |
Abstract
Psychedelic-assisted therapy and neurostimulation represent converging approaches to modulating dysfunctional brain circuits in treatment-resistant psychiatric disorders. This Perspective outlines shared mechanisms involving neuroplasticity and network reconfiguration, and examines ethical, regulatory, and infrastructural barriers to their translation. Bridging neuroscience, psychiatry, and policy, it proposes strategies for integrating these innovative interventions into evidence-based, circuit-focused models of mental health care.